Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Front Oncol：panHER抑制剂抗癌的潜力

2015-02-23 范伟 MedSci原创

抗癌panHER抑制剂
关注

目的：过度激活的 HER(erbB)家族的受体，HER1 - 4，导致三个重要信号通路的上调：有丝分裂原激活蛋白激酶、磷酸肌醇3-激酶/蛋白激酶B，和Janus激酶/信号转导和转录激活通路。抑制HER1 /EGFR具有有限的抗癌效果，由于二次突变，如T790M或旁路信号的其他HER成员。抗panHER的出现通过抑制这些通路抵抗突变提供了一个解决方案，作为一种新的癌症治疗方法。本文旨在概述HER信号

目的：过度激活的 HER(erbB)家族的受体，HER1 - 4，导致三个重要信号通路的上调：有丝分裂原激活蛋白激酶、磷酸肌醇3-激酶/蛋白激酶B，和Janus激酶/信号转导和转录激活通路。抑制HER1 /EGFR具有有限的抗癌效果，由于二次突变，如T790M或旁路信号的其他HER成员。抗panHER的出现通过抑制这些通路抵抗突变提供了一个解决方案，作为一种新的癌症治疗方法。本文旨在概述HER信号通路以及其参与肿瘤的进程，验证panHER抑制在抗癌方面的进展。

方法：与HER相关的信号通路的最近文献，通过PubMed和Medline数据库总结panHER抑制的研究，然后再进行比较和分析。

结果：panHER抑制剂的临床前研究和临床试验显示较有前景的结果，并可能改善癌症病人的治疗效果。

结论：对于HER家族过度活化的癌症如其他上皮癌和肉瘤，panHER抑制剂的使用是一个新的研究方向，在未来临床上对于癌症治疗有较大潜力。

原始出处

Wang X, Batty KM, Crowe PJ, Goldstein D, Yang JL.The Potential of panHER Inhibition in Cancer.Front Oncol. 2015 Jan 28;5:2. doi: 10.3389/fonc.2015.00002. eCollection 2015.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864606, encodeId=c4991864606ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 25 20:37:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851228, encodeId=5461185122873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 22 19:37:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23703, encodeId=59ef23e03b4, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16853, encodeId=117916853c2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:13:00 CST 2015, time=2015-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16814, encodeId=a8cf1681469, content=潜力很大的抗癌靶点～, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Tue Feb 24 10:18:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-03-25 minlingfeng

    #Oncol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1864606, encodeId=c4991864606ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 25 20:37:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851228, encodeId=5461185122873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 22 19:37:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23703, encodeId=59ef23e03b4, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16853, encodeId=117916853c2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:13:00 CST 2015, time=2015-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16814, encodeId=a8cf1681469, content=潜力很大的抗癌靶点～, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Tue Feb 24 10:18:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-04-22 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1864606, encodeId=c4991864606ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 25 20:37:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851228, encodeId=5461185122873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 22 19:37:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23703, encodeId=59ef23e03b4, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16853, encodeId=117916853c2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:13:00 CST 2015, time=2015-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16814, encodeId=a8cf1681469, content=潜力很大的抗癌靶点～, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Tue Feb 24 10:18:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-05-16 ljjj1053

    很不错学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1864606, encodeId=c4991864606ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 25 20:37:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851228, encodeId=5461185122873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 22 19:37:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23703, encodeId=59ef23e03b4, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16853, encodeId=117916853c2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:13:00 CST 2015, time=2015-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16814, encodeId=a8cf1681469, content=潜力很大的抗癌靶点～, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Tue Feb 24 10:18:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-02-24 orthoW

    不错的文章，学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1864606, encodeId=c4991864606ef, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 25 20:37:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851228, encodeId=5461185122873, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Apr 22 19:37:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23703, encodeId=59ef23e03b4, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:31:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16853, encodeId=117916853c2, content=不错的文章，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Tue Feb 24 11:13:00 CST 2015, time=2015-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16814, encodeId=a8cf1681469, content=潜力很大的抗癌靶点～, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Tue Feb 24 10:18:00 CST 2015, time=2015-02-24, status=1, ipAttribution=)]
    2015-02-24 weiwei881111

    潜力很大的抗癌靶点～

    0

相关资讯

PNAS：新药（ADI-PEG20）的抗癌新机制

加州大学戴维斯分校，台北医科大学和国家卫生研究院研究人员已发现了正处于临床研究阶段的癌症治疗药物（ADI-PEG20），杀死癌细胞的潜在新作用机制，研究揭示了该药物如何剥夺对细胞重要的关键氨基酸，特异性杀死肿瘤细胞。 他们的论文发表在PNAS杂志上。传统的癌症疗法包括化疗和放疗，但这往往有副作用。一种新出现的癌症治疗策略是“饿死”癌细胞，导致其死亡。利用正常细胞和肿瘤细胞不同的代谢需求，

用于抗癌的嵌合抗原受体T细胞疗法目前已经进入临床试验阶段

由达特茅斯Norris癌症研究中心Sentman实验室开发的抗癌嵌合抗原受体（Chimeric antigen receptor，CAR）T细胞目前正在进行临床I阶段的试验研究，研究者Charles Sentman教授表示，我们开发的CAR疗法在很多不同的癌症治疗中都具有广泛的应用价值，后期研究显示，CAR疗法不仅可以消除实验动物机体中的肿瘤，而且有效抑制癌症的复发。 CN-CS1是首次进入临床

Cancer Cell：抗体特定形式对刺激免疫系统抗癌至关重要

近日，南安普敦大学科学家发现，抗体的精确形状对如何刺激机体的免疫系统来对抗癌症有很大的区别，这就为设计更有效的治疗方法铺平了道路。癌症的最新类型治疗方法的目的是对免疫系统进行转换，使患者自身的免疫细胞能攻击和杀死癌细胞。 发表在Cancer Cell杂志上的一项研究中，研究人员发现对于刺激抗肿瘤免疫力，抗体的一种特殊形式IgG2b比其他类型更有效。该小组还已经能够设计锁定在特定形状（称为锁定

是好药总会出彩---段雪藏10年的抗癌药研发历程

癌症治疗进展可能令人沮丧。一种新疗法往往只能拖延疾病几周时间。然而，在日前于美国圣迭戈举行的癌症会议上，加州大学洛杉矶分校（UCLA）肿瘤学家Richard Finn报告称，在标准治疗中增加一种名为palbociclib的药物，能使转移性乳腺癌患者未出现新肿瘤的时间加倍，从平均10个月增加到20个月。“尽管一直在努力，但没有研究显示，增加一种新药后，无进展生存期会出现戏剧性改善。”Finn说。

Bind抗癌药物BIND-014二期研究数据喜忧参半

对于今年的Bind Therapeutics公司来说，太需要一场胜利来提振公司士气。今年早些时候，安进公司结束了与Bind Therapeutics公司的合作关系，这也意味着双方价值1亿8千万美元的癌症联合疗法合作正式划上句号。最近，Bind Therapeutics公司又公布了其纳米疗法BIND-014治疗非细小型细胞肺癌的二期临床研究数据。 BIND-014是Bind Therapeut

PNAS：更佳纳米颗粒尺寸让抗癌效应很大化

纳米医学的重要一部分是纳米颗粒，纳米颗粒装载药物靶向递送到特定的组织和细胞，是用于癌症诊断和治疗的新方案。了解纳米医学的物理化学性质关系到它们的生物学反应和功能，并对开发高效抗症斗士（抗癌纳米颗粒）至关重要。 材料科学和工程学副教授Jianjun Cheng解释：为了开发下一代具有超强的防癌抗癌属性的纳米医学颗粒，我们必须了解它们的物理化学性质（具体而言是颗粒大小）与机体生物系统之间的相互

Baidu
map
Baidu
map
Baidu
map